STOCK TITAN

Major Nuo Therapeutics (AURX) holder details 12% secured loans and new warrants

(High)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Nuo Therapeutics investor Scott M. Pittman updated his ownership and financing arrangements with the company. He now beneficially owns 5,627,500 shares of common stock, or 11.6% of the class, based on 48,408,728 shares outstanding as of May 29, 2026.

Pittman participated as a lender under a Loan and Security Agreement and an Amended and Restated Loan and Security Agreement, providing a $200,000 initial loan and a $100,000 interim loan, with an additional $100,000 commitment for a potential second closing. The secured notes bear 12% annual interest through December 31, 2028, with interest and certain prepayment fees payable in warrants rather than cash.

In connection with these loans, he received multiple series of warrants with a $1.50 per share exercise price, including Initial Warrants for 30,050 shares, Interim Warrants for 17,450 shares, Second Restated Warrants for 17,500 shares, Prepayment Restated Warrants for up to 7,333 shares, and an Interest Warrant issuable for up to 59,333 shares at maturity or earlier prepayment.

Positive

  • None.

Negative

  • None.

Insights

Pittman’s 12% secured loans and warrant package deepen his role as a key creditor-shareholder.

Scott M. Pittman has extended and restructured financing to Nuo Therapeutics through secured notes maturing on December 31, 2028. He provided a $200,000 initial loan, a $100,000 interim loan, and committed another $100,000 for a possible second closing.

The notes carry a 12% annual interest rate, with interest and prepayment fees paid in equity-linked warrants instead of cash. This reduces near-term cash outflows for the company but increases potential future share issuance at a $1.50 exercise price.

Pittman’s total beneficial ownership of 5,627,500 shares, or 11.6% of the common stock as of May 29, 2026, reflects both existing shares and vested options and warrants. Subsequent company filings may show how often prepayment triggers or interest accrual translate into additional warrant exercises.

Beneficial ownership 5,627,500 shares Common stock beneficially owned by Scott M. Pittman
Ownership percentage 11.6% Percent of class based on 48,408,728 shares outstanding as of May 29, 2026
Shares outstanding 48,408,728 shares Common stock outstanding as of May 29, 2026
Initial loan amount $200,000 Loaned at Initial Closing on January 23, 2026
Interim loan amount $100,000 Loaned at Interim Closing on May 29, 2026
Note interest rate 12% per annum Amended rate on Initial Notes and rate on Interim and Second Notes
Warrant exercise price $1.50 per share Exercise price for all related warrant series
Interest Warrant size up to 59,333 shares Shares issuable to Pittman at maturity or earlier prepayment
Loan and Security Agreement financial
"the closing (the "Initial Closing") occurred of a Loan and Security Agreement dated January 21, 2026"
A loan and security agreement is a legal contract that sets out the amount, repayment schedule, interest and the rules a borrower must follow, and it names specific assets a lender can claim if the borrower fails to pay. Think of it like a mortgage or car loan where the lender holds a claim on collateral until the debt is repaid. Investors care because it determines a company’s repayment priorities, borrowing costs, operational limits and how easily creditors can seize assets in distress, all of which affect equity value and credit risk.
Secured Promissory Note financial
"the Company issued a Secured Promissory Note (the "Initial Note") to each of the lenders"
A secured promissory note is a written promise to repay borrowed money that is backed by specific assets pledged as collateral; if the borrower fails to pay, the lender can seize those assets to recover losses. Investors care because the collateral reduces the lender’s risk and can make the loan safer and more likely to be repaid, similar to a pawnshop loan where an item lowers the lender’s exposure if the borrower defaults.
Interest Warrants financial
"Interest on the Notes will be payable in Interest Warrants as described below, and not in cash"
Prepayment Restated Warrants financial
"the Prepayment fee, if any, is payable in Prepayment Restated Warrants as described below"
beneficially owns financial
"As a result, the Reporting Person beneficially owns 5,627,500 shares of Common Stock"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
anti-dilution financial
"Each of the warrants contains provisions for anti-dilution and certain other adjustments"
A provision that protects an investor’s ownership stake or the value of convertible securities when a company issues new shares at a lower price. It adjusts the investor’s number of shares or the conversion price so their percentage of ownership or economic interest isn’t unfairly reduced — like getting a bigger slice of cake if the baker cuts more pieces, preserving your share of the whole.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Nuo Therapeutics (AURX) shares does Scott Pittman beneficially own after this amendment?

Scott M. Pittman beneficially owns 5,627,500 shares of Nuo Therapeutics common stock. This total includes 5,400,000 shares held directly, 47,500 shares issuable from vested warrants, and 180,000 shares issuable from options, representing 11.6% of the class based on 48,408,728 shares outstanding.

What percentage of Nuo Therapeutics (AURX) does Scott Pittman control under this Schedule 13D/A?

Scott M. Pittman reports beneficial ownership of 11.6% of Nuo Therapeutics’ common stock. This percentage is calculated using 48,408,728 shares outstanding as of May 29, 2026, as represented by the company in the Amended and Restated Loan and Security Agreement.

What loans did Scott Pittman provide to Nuo Therapeutics (AURX) in 2026?

Pittman loaned $200,000 at the initial January 23, 2026 closing and $100,000 at the May 29, 2026 interim closing. He also committed to loaning an additional $100,000 at a potential second closing on September 30, 2026, under the amended and restated loan terms.

What are the key terms of the notes Nuo Therapeutics (AURX) issued to Scott Pittman?

The secured notes issued to Pittman bear 12% annual interest and mature on December 31, 2028. They are interest-only through December 31, 2026, with principal repaid quarterly starting March 31, 2027. Interest and certain prepayment fees are payable in warrants rather than cash.

What warrant rights did Scott Pittman receive from Nuo Therapeutics (AURX)?

Pittman received several warrant series with a $1.50 exercise price, including Initial Warrants for 30,050 shares, Interim Warrants for 17,450 shares, Second Restated Warrants for 17,500 shares, Prepayment Restated Warrants for up to 7,333 shares, and an Interest Warrant issuable for up to 59,333 shares.

How is Nuo Therapeutics (AURX) required to prepay the notes held by Scott Pittman?

Prepayment is mandatory upon an equity financing of at least $5 million, certain changes in control, or a default. In these cases, Nuo must pay outstanding principal and accrued interest, plus a prepayment fee of 2.75% or 1.5%, payable in Prepayment Restated Warrants instead of cash.





67059V209

(CUSIP Number)
Scott M. Pittman
c/o Nuo Therapeutics, Inc., 8285 El Rio, Suite 190
Houston, TX, 77054
(346) 396-4770

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
05/29/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D


Pittman Scott M.
Signature:/s/ Scott M. Pittman
Name/Title:Scott M. Pittman
Date:06/03/2026